Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28746989 | 1.00 | THRB (0.33) | THRBLIPA | |
| SCHEMBL20453952 | 0.98 | THRB (0.34) | THRBLIPA | |
| SCHEMBL196683 | 0.98 | THRB (0.34) | THRBLIPA | |
| SCHEMBL9776033 | 0.96 | THRB (0.33) | THRBLIPA | |
| SCHEMBL29093088 | 0.96 | THRB (0.33) | THRBLIPA | |
| SCHEMBL15817269 | 0.96 | THRB (0.33) | THRBLIPA | |
| SCHEMBL10919609 | 0.96 | THRB (0.33) | THRBLIPA | |
| SCHEMBL28467362 | 0.96 | THRB (0.33) | THRBLIPA | |
| SCHEMBL8194781 | 0.96 | THRB (0.33) | THRBLIPA | |
| SCHEMBL8994614 | 0.96 | THRB (0.33) | THRBLIPA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-4176918-A | Fluorescent liquid crystal display | TEMPLE UNIVERSITY (US) | 1979-12-04 | — | — | US | claimed |
| CN-117603035-B | Chalcone derivative and preparation method and application thereof | 南开大学 | 2025-02-11 | — | — | CN | disclosed |
| CN-119186422-A | Preparation method of microsphere composition used in photo-excitation chemiluminescence immunoassay technology | 北京艾维镝生物技术有限责任公司 | 2024-12-27 | — | — | CN | disclosed |
| CN-116673067-B | High-purity alumina active sphere carrier and preparation method thereof | 扬州中天利新材料股份有限公司 | 2024-12-06 | — | — | CN | disclosed |
| CN-118873822-A | Treatment of gastrointestinal disorders with TNF inhibitors | 比奥拉治疗股份有限公司 | 2024-11-01 | — | — | CN | disclosed |
| CN-118791456-A | 3', 8-Disubstituted quercetin derivatives, preparation method and application thereof | 上海医药工业研究院有限公司 | 2024-10-18 | — | — | CN | disclosed |
| CN-115746010-B | Synthesis of flavonoid derivative and pharmaceutical application thereof | 南开大学 | 2024-10-15 | — | — | CN | disclosed |
| CN-116942656-B | Application of naringenin derivative in preparation of anti-pancreatitis medicine | 四川大学华西医院 | 2024-09-17 | — | — | CN | disclosed |
| CN-117603175-B | Chalcone derivative with benzopyran structure, and preparation method and application thereof | 南开大学 | 2024-08-06 | — | — | CN | disclosed |
| CN-115636809-B | Synthesis and pharmaceutical application of chalcone derivatives | 南开大学 | 2024-06-11 | — | — | CN | disclosed |
| US-11479537-B2 | T-type calcium channel inhibitor | KINKI UNIVERSITY (JP) | 2022-10-25 | — | — | US | disclosed |
| CN-114752374-A | Preparation method of microsphere composition used in homogeneous chemiluminescence immunoassay technology | 北京艾维镝生物技术有限责任公司 | 2022-07-15 | — | — | CN | disclosed |
| CN-114746740-A | Luminescence imaging for sensing | C2感官有限公司 | 2022-07-12 | — | — | CN | disclosed |
| CN-107298667-B | Method for synthesizing icaritin | 北京盛诺基医药科技股份有限公司 | 2020-09-08 | — | — | CN | disclosed |
| US-6723454-B2 | Luminescent device | KONINKLIJKE PHILIPS ELECTRONICS N.V. (NL) | 2004-04-20 | — | — | US | disclosed |
| EP-1090087-B1 | LUMINESCENT DEVICE | KONINKL PHILIPS ELECTRONICS NV (NL) | 2003-08-13 | — | — | EP | disclosed |
| US-20030012979-A1 | Luminescent device | KONINKLIJKE PHILIPS ELECTRONICS N.V. (NL) | 2003-01-16 | — | — | US | disclosed |
| EP-1090087-A1 | LUMINESCENT DEVICE | Koninklijke Philips Electronics N.V. (NL) | 2001-04-11 | — | — | EP | disclosed |
| WO-2000064996-A1 | LUMINESCENT DEVICE | KONINKLIJKE PHILIPS ELECTRONICS N.V. (NL) | 2000-11-02 | — | — | WO | disclosed |
| US-4176918-A | Fluorescent liquid crystal display | TEMPLE UNIVERSITY (US) | 1979-12-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11479537-B2 | T-type calcium channel inhibitor | CACNA1H, CACNA1I, CACNA1G | THRB 237/4885LIPA 4071/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.